Julie Hortelano

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

Christelle Remy‐Ziller, Christine Thioudellet, Julie Hortelano et al. · Human Vaccines & Immunotherapeutics · 2017 · 34 citations · Full text

Life Sciences, Immunology, Oncology +17

Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer

Jérémy Béguin, Johann Foloppe, Christelle Maurey et al. · Molecular Therapy — Oncolytics · 2020 · 27 citations · Full text

Medicine, Oncology, Pharmacology +16

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1

Patricia Kleinpeter, Christelle Remy‐Ziller, Eline Winter et al. · Journal of Virology · 2019 · 25 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors

Emmanuelle Schaedler, Christelle Remy‐Ziller, Julie Hortelano et al. · Vaccine · 2016 · 17 citations

Medicine, Immunology, Oncology +17

Yeast Virus-Derived Stimulator of the Innate Immune System Augments the Efficacy of Virus Vector-Based Immunotherapy

Marie‐Christine Claudepierre, Julie Hortelano, Emmanuelle Schaedler et al. · Journal of Virology · 2014 · 16 citations · Full text

Life Sciences, Immunology, Molecular Biology +17